Brian Cheek retweeted
International Business Times (@IBTimes) recently published an article exploring my investment thesis on @eXoZymes $EXOZ and the research I've been sharing through Slack Capital since early 2025!
ibtimes.com/why-exozymes-sta…
Since first discovering eXoZymes in January 2025, I've spent considerable time researching the company's cell-free biomanufacturing technology and its commercial potential. The more I've learned, the more convinced I've become that eXoZymes represents one of the most significant asymmetric investment opportunities I've ever encountered.
The article highlights one of the central reasons behind my conviction... eXoZymes' potential to build a compounding value flywheel.
@eXoZymes isn't simply developing another single molecule based on binary risk . The company is building a platform designed to repeatedly identify highly valuable molecules, develop the Exozyme systems required to manufacture them and bring these molecules to market.
The potential is that each successful programme makes the next one easier to develop and commercialise. As eXoZymes builds its technical expertise, manufacturing capabilities and commercial partnerships, it could create a foundation for an expanding portfolio of valuable molecules.
We're beginning to see encouraging progress with the company's leading NCT programme, which has already achieved significant manufacturing milestones and is now advancing towards commercial-scale production.
While there is still plenty to prove, I believe the opportunity for eXoZymes to repeat this process across multiple molecules is what makes its long-term potential so compelling.
You can read the International Business Times article here:
ibtimes.com/why-exozymes-sta…
Slack Capital: Inside EXOZ’ strategic shift - building a compounding value flywheel
How @eXoZymes’ new strategy of retaining, de-risking and monetising high-value assets could create a self-reinforcing flywheel of value creation
The full research report from @Slack_Capital is freely available here:
na2.hubs.ly/H07t8HP0 $EXOZ
Brian Cheek retweeted
Replying to @eXoZymes
@eXoZymes $EXOZ cannabinoid-like program isn’t about creating a 'new THC' product. It’s about engineering an extensive, high-value portfolio of programmable chemical scaffolds, designed to deliver highly potent, targeted therapeutics across massive global disease indications.
At its core, nature is fundamentally constrained. A hemp plant is limited by its fixed set of enzymes and genome, allowing only ~150 naturally occurring phytocannabinoids. Expanding beyond this amount would require millions of years of evolution to reconfigure the plant's enzymes. As these cannabinoids evolved for the plant’s own survival, not for human therapeutics, they tend to be generally low potency and broadly acting.
By contrast, in @eXoZymes' cell-free system, every enzymatic step is modular and highly programmable. This allows the company to rapidly design cannabinoid-like analogs tailored specifically for high-need indications spanning pain, inflammation, and metabolic disease.
Traditional phytocannabinoids (THC, CBD, etc.) are restricted to a few molecular 'dials': a resorcinol core, an alkyl side chain, a prenyl/terpene unit and a ring system. @eXoZymes builds upon this baseline by introducing new-to-nature structural features to its analogs.
By systematically tuning even a single molecular 'dial', @eXoZymes cell-free platform can achieve a molecular design with amplified therapeutic potency and target selectivity that nature simply cannot replicate. This unlocks a massive design space, enabling the rapid generation of tens of thousands of novel, highly optimized analog structures.
That design space is already generating significant commercial momentum. Having isolated the most therapeutically viable designs, @eXoZymes has advanced 9 lead candidates into in-vitro testing, with further analogs in the pipeline.
Crucially, this is only the beginning. @eXoZymes cell-free platform goes far beyond a single-asset cannabinoid play, it's a repeatable, highly scalable discovery engine for new-to-nature pharmaceutical analogs across diverse molecular classes. The company has already generated multiple NCT analogs and is also rapidly accelerating them through preclinical evaluation.
Brian Cheek retweeted
eXoZymes (@eXoZymes) (Nasdaq: EXOZ) makes its case for cell-free biomanufacturing, the approach it says sidesteps where whole-cell synthetic biology has repeatedly failed to scale.
Whole-cell synthetic biology has a long record of stalling at scale. In a Webull webinar, eXoZymes Chief Commercial Officer Damien Perriman laid out why the company removed the cell from the equation entirely.
eXoZymes Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's profile at b2idigital.com/exozymes-1
"Engineered cells have become a boulevard of broken dreams on Wall Street, and eXoZymes found a way to navigate around this problem," said Damien Perryman, Chief Commercial Officer of eXoZymes.
In the webinar, Perryman also covered:
• Cells evolved to survive, not to manufacture, so whole-cell systems carry biological noise, toxicity limits, and regulatory complexity into production
• eXoZymes isolates the enzymes, engineers them with AI, and runs them outside the cell to produce target molecules cleanly and at scale
• The result behaves more like precision chemistry than a biological production system, inspired by biology's own catalysts
Watch the full webinar: youtube.com/watch?v=OmH3TaaM…
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Brian Cheek retweeted
While @exozymes’ NCT and cannabinoid-like programs are likely to become standalone multi-billion dollar opportunities, their commercial launch ultimately serves a greater purpose... validating the company's cell-free biomanufacturing platform
This is just the first turn of eXoZymes’ flywheel engine!
Most biotech companies are built around a single asset, where success or failure depends on a binary outcome. @eXoZymes is different... the company is designed to repeatedly create, validate and scale high-value compounds across nutraceuticals, pharmaceuticals and beyond
eXoZymes' flywheel works like this:
→ Each compound validates the platform's capabilities
→ Validation attracts partners and licensing deals
→ Each new deal expands the revenue base
→ Revenue accelerates future compound launches
Already, @eXoZymes has 30+ high-impact compounds in its pipeline and is seeing growing interest from pharmaceutical partners
With the two initial programs targeting a combined TAM of $200B, these are not isolated opportunities... they represent the first turns of a continuous flywheel, compounding value back to $EXOZ shareholders
Coming soon NCT by $EXOZ Exozymes to address many of the issues related to mitochondria distruction - previous undruggable compounds are on the way @thegarybrecka
Every cell in your body contains between 1,000 and 2,500 mitochondria.
They produce 90% of your cellular energy. They regulate inflammation, hormone production, and even the aging process itself.
Mitochondrial dysfunction is now linked to virtually every chronic disease: from Alzheimer's to Type 2 diabetes to cancer.
What improves mitochondrial function: cold exposure, heat therapy, high-intensity interval training, red light therapy, CoQ10, B vitamins, and quality sleep.
Your energy levels are a direct reflection of mitochondrial health. Treat them accordingly.
4
159
Case study from @Springwise featuring Damien @Perriman: Unpacking how eXoZymes and Cayman Chemical are rethinking chemical manufacturing.
@eXoZymes takes enzyme pathways from biology and brings them into the world of chemistry. @CaymanChemical is helping to scale this novel approach
Full case study available here:
na2.hubs.ly/H04Xthr0 $EXOZ
Brian Cheek retweeted
Come join the community lead @eXoZymes Investor Discord! 🧬 $EXOZ
discord.gg/JyfWH5gS
One of the best places to connect with other shareholders and stay up to date with all the company's developments
NCT, although very well known for its metabolic benefits, until now has not been able to be produced at scale and purity @CaseyMeansMD @hubermanlab @drmarkhyman @PeterAttiaMD
Grow Everything podcast: In this episode, Damien Perriman, CCO of @eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules.
@Perriman states: “eXoZymes is building a disciplined model for bridging invention and market delivery. We remain focused on creating better ways to make important molecules, while vehicles like NCTx are designed to take those opportunities into the market with speed and purpose. When our process performs successfully in someone else’s hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform.”
Full @messaginglab podcast episode available as both video and audio here:
exozymes.com/blog/grow-every…
#exozymes #cellfree #biomanufacturing $EXOZ
Did you hear @erumazeez's excellent question to @Perriman: "Okay, so if NCT were a superhero, what would its superpower be?"
Hint: It's not your usual superhero... check out the answer in the video below!
The entire podcast episode is definitely worth a listen if you care about where biotech - and biomanufacturing - are actually heading:
exozymes.com/blog/grow-every…
$EXOZ #exozymes #exozyme #enzymes #enzyme #biomanufacturing #biotech #synbio
Brian Cheek retweeted
Looking forward to @eXoZymes NCTx's Human Use Studies this QUARTER & their Pharmaceutical Analogues preclinical program in H2 2026
If the science proves out, the opportunity here is massive. 1.4+ billion people worldwide are affected by obesity, diabetes & metabolic dysfunction
From The @villagevoice: The Metabolic Engine - How Scientists Are Exploring a New Path Beyond GLP-1 Weight-Loss Drugs
America’s weight-loss conversation has changed almost overnight. Prescription drugs once reserved for diabetes treatment are now household names, promising dramatic results on the scale. Many therapies currently available focus on reducing appetite or limiting calorie intake, which can certainly lead to weight loss. Yet those solutions often address the symptom rather than the deeper metabolic engine driving the condition.
Interest is growing around strategies that target the body’s internal energy system itself. Instead of simply telling the body to eat less, researchers are investigating ways to improve how the body burns energy, processes fat, and maintains metabolic balance. That shift in thinking has opened the door to a small but intriguing molecule known as N-trans-Caffeoyltyramine, or NCT.
Full story available here:
na2.hubs.ly/H04N4_c0
Brian Cheek retweeted
Replying to @eXoZymes
Brian Cheek retweeted
The shift in @eXoZymes underlying narrative is undeniable... the technology is delivering unprecedented results and the commercial opportunity is becoming impossible to ignore
An incredibly exciting period ahead for the company, investors and the future of biomanufacturing!
CCO at @eXoZymes, Damien Perriman, interviewed at @Nasdaq around our NCT project:
"We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine."
#exozymes #exozyme #enzymes #enzyme #NCT #Nasdaq #ntranscaffeoyltyramine $EXOZ
In a recent episode of The Big Skinny - the SportsCenter of Financial News - @FoxBusiness contributor, @LouBasenese, stated:
"@eXoZymes is a new way to create chemicals. It's like the @BASF of the 2026 [...] We don't make a lot of the products you buy. We make a lot of the products you buy better."
Full episode available here:
na2.hubs.ly/H03YqQD0
#exozymes #exozyme #enzymes #enzyme #biomanufacturing $EXOZ
Brian Cheek retweeted
A must watch for those interested in @eXoZymes!
Three of the company’s heavy hitters sit down and discuss the events of 2025 as well as the MASSIVE opportunities in 2026 and beyond
It's time for another Heltzen's Video Highlight: 2025 in Review and Looking Ahead! In this video, I'm having conversations with our CSO, Tyler, and our CCO, Damien, about what happened last year and what we anticipate happening this year.
Full video available here:
na2.hubs.ly/H02S7b90
Brian Cheek retweeted
It's time for another Heltzen's Video Highlight: 2025 in Review and Looking Ahead! In this video, I'm having conversations with our CSO, Tyler, and our CCO, Damien, about what happened last year and what we anticipate happening this year.
Full video available here:
na2.hubs.ly/H02S7b90
Brian Cheek retweeted
Replying to @eXoZymes
@eXoZymes announces a major de-risking event for its NCT compound 🎯📈
The successful pilot-plant demonstration of 100x scale-up and >99% conversion yield confirms the path to unlocking NCT's multi-billion dollar market opportunity towards the end of 2026 $EXOZ
Brian Cheek retweeted
We've set up a new Discord server for @eXoZymes $EXOZ investors! Come join the future of biomanufacturing👇
discord.gg/AzSr8QdR
Brian Cheek retweeted
We're super excited to announce the successful achievement of a 100-fold scale-up of our NCT production process! Producing this externally with @CaymanChemical, we even managed a conversion level of over 99% from feedstock to product! This marks a major milestone in the scalability of our exozymes platform.
Michael @heltzen, CEO of @eXoZymes, “We’re very enthusiastic about this progress and see it as an important inflection point in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale. This truly opens the door to producing molecules that have historically been constrained by traditional manufacturing approaches.”
Full story here:
na2.hubs.ly/H02x4HF0
#exozymes #exozyme #enzymes #enzyme #biomanufacturing #NCT $EXOZ
Brian Cheek retweeted
"There are moments in science when something small and elusive suddenly becomes attainable, when a molecule trapped in the fine print of research papers becomes the centerpiece of an entirely new chapter in health. That is what happened when eXoZymes turned its attention to plant-derived N-trans-caffeoyltyramine (NCT), an investigational compound with the potential to change how the world treats chronic metabolic and inflammatory diseases."
“The beauty of leading with NCT,” said Damien Perriman (@Perriman), eXoZymes’ Chief Commercial Officer, “is that we’ve taken something nature only whispers about and figured out how to make it into something we can actually use, because we can provide it at scale.”
Full @VanityFair article available here:
na2.hubs.ly/H02d-Lq0
#exozymes #exozyme #enzymes #enzyme #nct #nctx #biomanufacturing #biosolutions














